Genomic sequencing used to help identify new therapies for bile duct cancer

Date:

February 13, 2014

Source:

Mayo Clinic

Summary:

Physicians have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies. Potential new treatment approaches are being validated to develop new tests that physicians can use to guide therapy for this aggressive cancer of the bile ducts that progresses quickly and is difficult to treat.

Share:

Total shares:

FULL STORY

A patients' tumors from cholangiocarcinoma, a rare liver cancer that typically fails chemotherapy, shrunk significantly after treatment with FGFR inhibitors, which were prescribed based on results of next generation sequencing. The drugs used, pazopanib (top) and ponatinib, are typically used to treat kidney cancer and certain types of leukemia, respectively.

Credit: Image courtesy of Mayo Clinic

A patients' tumors from cholangiocarcinoma, a rare liver cancer that typically fails chemotherapy, shrunk significantly after treatment with FGFR inhibitors, which were prescribed based on results of next generation sequencing. The drugs used, pazopanib (top) and ponatinib, are typically used to treat kidney cancer and certain types of leukemia, respectively.

Credit: Image courtesy of Mayo Clinic

Physicians at Mayo Clinic’s Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies. Potential new treatment approaches are being validated to develop new tests that physicians can use to guide therapy for this aggressive cancer of the bile ducts that progresses quickly and is difficult to treat.

Clinically important findings suggest that targeting the epidermal growth factor receptor (EGFR) and the fibroblast growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease, according to the study published today in the journal PLOS Genetics.

Half of the patients treated in this study responded to either ponatinib (typically used for certain types of leukemia) or pazopinib (a kidney cancer drug), depending on the genetic alterations identified through sequencing.

“In 3 out of the 6 patients we analyzed, we found compelling, treatable and unexpected genetic alterations that would never have been found by normal testing methods for cholangiocarcinoma,” says Mitesh Borad, M.D., a Mayo Clinic oncologist and lead author of the paper. “We treated these three patients with drugs that attack these genetic alterations and saw tumor shrinkage. This gives us hope for better treatments for this aggressive, hard-to-treat cancer.”

Because of these encouraging early results, the team of 49 doctors and researchers proposes large-scale clinical trials to test EFGR and FGFR inhibitors as possible treatments for biliary tract cancers that harbor mutations in these genes and pathways.

“Our results demonstrate that if we find the right molecular context, more appropriate therapies can be chosen that improve outcomes,” says John Carpten, Ph.D., TGen deputy director of basic science and director of TGen’s Integrated Cancer Genomics Division, and the study’s senior author. “We now hope to design larger clinical studies to treat patients’ tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced cholangiocarcinoma.”

Bile duct cancer is a rare cancer that occurs mostly in people older than age 50. Surgical approaches, such as resection and liver transplantation, represent the only curative treatment approaches, says Dr. Borad. Most patients, however, present with surgically unresectable or metastatic disease at the time of diagnosis. Standard-of-care chemotherapies are not curative and there is an unmet need for newer approaches, Dr. Borad adds.

Story Source:

The above post is reprinted from materials provided by Mayo Clinic. Note: Materials may be edited for content and length.

Mayo Clinic. "Genomic sequencing used to help identify new therapies for bile duct cancer." ScienceDaily. ScienceDaily, 13 February 2014. <www.sciencedaily.com/releases/2014/02/140213184651.htm>.

Mayo Clinic. (2014, February 13). Genomic sequencing used to help identify new therapies for bile duct cancer. ScienceDaily. Retrieved August 2, 2015 from www.sciencedaily.com/releases/2014/02/140213184651.htm

Mayo Clinic. "Genomic sequencing used to help identify new therapies for bile duct cancer." ScienceDaily. www.sciencedaily.com/releases/2014/02/140213184651.htm (accessed August 2, 2015).

July 31, 2015  School is just around the corner, which means backpacks and packed lunches await your children. One expert offers tips for parents to promote healthy dental habits while away from ... read more

July 29, 2015  By blocking the expression of a certain gene in patients, researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their ... read more

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

Feb. 17, 2015  Patients with bile duct cancer could be helped by a new class of experimental drug, a laboratory study has shown. Experimental drugs that block the wnt pathway are already being tested in patients ... read more

Oct. 14, 2013  A marker in bile known as vascular endothelial growth factor (VEGF) plays an important role in the growth of cancerous tumors according to new research. Researchers found that VEGF levels from bile ... read more

May 14, 2012  Scientists have made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct ... read more

Oct. 26, 2010  Researchers have taken a big step toward understanding what causes one of the most serious liver diseases in infants. The disease is called biliary atresia. It blocks the bile ducts in young infants. ... read more